Duration of humoral immunity from smallpox vaccination and its cross-reaction with Mpox virus.
Journal
Signal transduction and targeted therapy
ISSN: 2059-3635
Titre abrégé: Signal Transduct Target Ther
Pays: England
ID NLM: 101676423
Informations de publication
Date de publication:
15 09 2023
15 09 2023
Historique:
received:
13
02
2023
accepted:
26
07
2023
revised:
11
06
2023
medline:
18
9
2023
pubmed:
15
9
2023
entrez:
14
9
2023
Statut:
epublish
Résumé
The ongoing pandemic caused by mpox virus (MPXV) has become an international public health emergency that poses a significant threat to global health. The vaccinia virus Tiantan strain (VTT) was used to vaccinate against smallpox in China 42 years ago. It is urgent to assess the level of immunity to smallpox in individuals vaccinated 43 or more years ago and evaluate their immunological susceptibility to MPXV. Here, we recruited 294 volunteers and detected the level of residual humoral immunity, including the vaccinia-specific IgG level and neutralizing antibody titer, and the cross-antibodies of MPXV A29L, B6R, A35R, and M1R. Our results showed that the humoral immunity from the smallpox vaccine in the population still remains, and VTT-specific NAb levels wane with age. The majority of the population pre-1981 who should be immunized with VTT still maintains certain levels of MPXV-specific antibodies, in particular, targeting A35R and B6R antigens. Furthermore, we separately analyzed the correlations between the OD450 values of VTT-specific IgG and A35R-specific IgG, B6R-specific IgG, and A29L-specific IgG with plasma samples diluted 1:40, showing a linear correlation (p < 0.0001). Our findings suggest that most Chinese populations still maintain VTT-specific IgG antibodies for 42 or more years after smallpox vaccination and could provide some level of protection against MPXV.
Identifiants
pubmed: 37709783
doi: 10.1038/s41392-023-01574-6
pii: 10.1038/s41392-023-01574-6
pmc: PMC10502045
doi:
Substances chimiques
Antibodies, Neutralizing
0
Immunoglobulin G
0
Smallpox Vaccine
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
350Informations de copyright
© 2023. West China Hospital, Sichuan University.
Références
Petersen, E. et al. Human Monkeypox: epidemiologic and clinical characteristics, diagnosis, and prevention. Infect. Dis. Clin. North Am. 33, 1027–1043 (2019).
doi: 10.1016/j.idc.2019.03.001
pubmed: 30981594
pmcid: 9533922
Breman, J. G. et al. Human monkeypox, 1970-79. Bull. World Health Organ. 58, 165–182 (1980).
pubmed: 6249508
pmcid: 2395797
Bunge, E. M. et al. The changing epidemiology of human monkeypox-A potential threat? A systematic review. PLoS Negl. Trop. Dis. 16, e0010141 (2022).
doi: 10.1371/journal.pntd.0010141
pubmed: 35148313
pmcid: 8870502
Costello, V. et al. Imported Monkeypox from International Traveler, Maryland, USA, 2021. Emerg. Infect. Dis. 28, 1002–1005 (2022).
doi: 10.3201/eid2805.220292
pubmed: 35263559
pmcid: 9045429
Hobson, G., et al. Family cluster of three cases of monkeypox imported from Nigeria to the United Kingdom, May 2021. Euro. Surveill. 26, 2100745 (2021).
Erez, N. et al. Diagnosis of imported Monkeypox, Israel, 2018. Emerg. Infect. Dis. 25, 980–983 (2019).
doi: 10.3201/eid2505.190076
pubmed: 30848724
pmcid: 6478227
WHO. WHO Director-General’s statement at the press conference following IHR Emergency Committee regarding the multi-country outbreak of monkeypox—23 July 2022. https://www.who.int/director-general/speeches/detail/who-director-general-s-statement-on-the-press-conference-following-IHR-emergency-committee-regarding-the-multi--country-outbreak-of-monkeypox--23-july-2022 . (WHO, 2022).
CDC. 2022 Global Map & Case Count. https://www.cdc.gov/poxvirus/mpox/response/2022/world-map.html . (CDC, 2023).
Fine, P. E., Jezek, Z., Grab, B. & Dixon, H. The transmission potential of monkeypox virus in human populations. Int. J. Epidemiol. 17, 643–650 (1988).
doi: 10.1093/ije/17.3.643
pubmed: 2850277
Henderson, D. A. The eradication of smallpox–an overview of the past, present, and future. Vaccine 29, D7–D9 (2011).
doi: 10.1016/j.vaccine.2011.06.080
pubmed: 22188929
Kim, S. H. et al. The persistence of humoral and cellular immunities more than three decades after smallpox vaccination. Clin. Microbiol. Infect. 13, 91–93 (2007).
doi: 10.1111/j.1469-0691.2006.01576.x
pubmed: 17184294
Amanna, I. J., Slifka, M. K. & Crotty, S. Immunity and immunological memory following smallpox vaccination. Immunol. Rev. 211, 320–337 (2006).
doi: 10.1111/j.0105-2896.2006.00392.x
pubmed: 16824139
Mooi, F. R., Van Der Maas, N. A. & De Melker, H. E. Pertussis resurgence: waning immunity and pathogen adaptation—two sides of the same coin. Epidemiol. Infect. 142, 685–694 (2014).
doi: 10.1017/S0950268813000071
pubmed: 23406868
Heffernan, J. M. & Keeling, M. J. Implications of vaccination and waning immunity. Proc. Biol. Sci. 276, 2071–2080 (2009).
pubmed: 19324753
pmcid: 2677258
Shchelkunov, S. N. An increasing danger of zoonotic orthopoxvirus infections. PLoS Pathog. 9, e1003756 (2013).
doi: 10.1371/journal.ppat.1003756
pubmed: 24339772
pmcid: 3855571
Nguyen, P. Y. et al. Reemergence of Human Monkeypox and declining population immunity in the context of urbanization, Nigeria, 2017-2020. Emerg. Infect. Dis. 27, 1007–1014 (2021).
doi: 10.3201/eid2704.203569
pubmed: 33756100
pmcid: 8007331
Nalca, A. & Zumbrun, E. E. ACAM2000: the new smallpox vaccine for United States Strategic National Stockpile. Drug Des. Devel. Ther. 4, 71–79 (2010).
doi: 10.2147/DDDT.S3687
pubmed: 20531961
pmcid: 2880337
Rizk, J. G. et al. Prevention and treatment of Monkeypox. Drugs 82, 957–963 (2022).
doi: 10.1007/s40265-022-01742-y
pubmed: 35763248
pmcid: 9244487
Xiang, Y. & White, A. Monkeypox virus emerges from the shadow of its more infamous cousin: family biology matters. Emerg. Microbes Infect. 11, 1768–1777 (2022).
doi: 10.1080/22221751.2022.2095309
pubmed: 35751396
pmcid: 9278444
FDA. FDA Approves First Live, Nonnon-replicating Vaccine to Prevent Smallpox and Monkeypox. https://www.fda.gov/news-events/press-announcements/fdaapproves-first-live-non-replicating-vaccine-prevent-smallpox-and-monkeypox . (FDA, 2019).
Yang, X. et al. The life cycle of Hyalomma scupense (Acari: Ixodidae) under laboratory conditions. Ticks Tick Borne Dis. 13, 102019 (2022).
doi: 10.1016/j.ttbdis.2022.102019
pubmed: 35963189
Thy, M. et al. Breakthrough infections after postexposure vaccination against Mpox. N. Engl J. Med. 387, 2477–2479 (2022).
doi: 10.1056/NEJMc2211944
pubmed: 36477495
Turner, M. et al. Monkeypox in patient immunized with ACAM2000 smallpox vaccine During 2022 Outbreak. Emerg. Infect. Dis. 28, 2336–2338 (2022).
doi: 10.3201/eid2811.221215
pubmed: 36104166
pmcid: 9622228
Poland, G. A., Kennedy, R. B. & Tosh, P. K. Prevention of monkeypox with vaccines: a rapid review. Lancet Infect. Dis. 22, e349–e358 (2022).
doi: 10.1016/S1473-3099(22)00574-6
pubmed: 36116460
pmcid: 9628950
Gong, Q., Wang, C., Chuai, X. & Chiu, S. Monkeypox virus: a re-emergent threat to humans. Virol. Sin. 37, 477–482 (2022).
doi: 10.1016/j.virs.2022.07.006
pubmed: 35820590
pmcid: 9437600
Yang, L. et al. Immunization of mice with vaccinia virus Tiantan strain yields antibodies cross-reactive with protective antigens of monkeypox virus. Virol. Sin. 38, 162–164 (2023).
doi: 10.1016/j.virs.2022.10.004
pubmed: 36272712
Panchanathan, V., Chaudhri, G. & Karupiah, G. Correlates of protective immunity in poxvirus infection: where does antibody stand? Immunol. Cell Biol. 86, 80–86 (2008).
doi: 10.1038/sj.icb.7100118
pubmed: 17923850
Mack, T. M., Noble, J. Jr & Thomas, D. B. A prospective study of serum antibody and protection against smallpox. Am. J. Trop. Med. Hyg. 21, 214–218 (1972).
doi: 10.4269/ajtmh.1972.21.214
pubmed: 5061278
Sarkar, J. K., Mitra, A. C. & Chakravarty, M. S. Relationship of clinical severity, antibody level, and previous vaccination state in smallpox. Trans. R. Soc. Trop. Med. Hyg. 66, 789–792 (1972).
doi: 10.1016/0035-9203(72)90095-8
pubmed: 4647651
Jezek, Z. et al. Human monkeypox: a study of 2,510 contacts of 214 patients. J. Infect. Dis. 154, 551–555 (1986).
doi: 10.1093/infdis/154.4.551
pubmed: 3018091
Davies, D. H. et al. Profiling the humoral immune response to infection by using proteome microarrays: high-throughput vaccine and diagnostic antigen discovery. Proc. Natl Acad. Sci. USA 102, 547–552 (2005).
doi: 10.1073/pnas.0408782102
pubmed: 15647345
pmcid: 545576
Gao, F. et al. Cross-reactive immune responses to monkeypox virus induced by MVA vaccination in mice. Virol. J. 20, 126 (2023).
doi: 10.1186/s12985-023-02085-0
pubmed: 37337226
pmcid: 10278293
Delaney, K. P. et al. Strategies adopted by gay, bisexual, and other men who have sex with men to prevent monkeypox virus transmission—United States, August 2022. MMWR Morb. Mortal Wkly Rept. 71, 1126–1130 (2022).
Hammarlund, E. et al. Duration of antiviral immunity after smallpox vaccination. Nat. Med. 9, 1131–1137 (2003).
doi: 10.1038/nm917
pubmed: 12925846
Hooper, J. W., Custer, D. M., Schmaljohn, C. S. & Schmaljohn, A. L. DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge. Virology. 266, 329–339 (2000).
doi: 10.1006/viro.1999.0096
pubmed: 10639319
Mucker, E. M. et al. A nucleic acid-based orthopoxvirus vaccine targeting the vaccinia virus L1, A27, B5, and A33 proteins protects rabbits against lethal rabbitpox virus aerosol challenge. J. Virol. 96, e0150421 (2022).
doi: 10.1128/JVI.01504-21
pubmed: 34851148